tiprankstipranks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market
IKT
Inhibikase Therapeutics
RESEARCH TOOLSreports

Inhibikase Therapeutics (IKT) Income Statement

377 Followers

Inhibikase Therapeutics Income Statement

Last quarter (Q4 2025), Inhibikase Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Inhibikase Therapeutics's net income was $-12.73M. See Inhibikase Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Mar 23Mar 22
Total Revenue
$ 0.00$ 0.00$ 260.50K$ 123.44K$ 3.10M
Gross Profit
$ -60.50K$ -26.27K$ -13.36M$ 116.72K$ -8.26M
Operating Expenses
$ 45.89M$ 28.56M$ 6.73M$ 18.25M$ 6.51M
Depreciation and Amortization
$ 60.50K$ 26.27K$ 177.40K$ 6.72K$ 14.77M
EBITDA
$ -45.89M$ -27.49M$ -19.91M$ -18.05M$ 0.00
Operating Income
$ -45.95M$ -28.59M$ -20.09M$ -18.13M$ -14.77M
Other Income/Expenses
$ -2.31M$ 1.07M$ 1.06M$ 74.45K$ -19.92K
Pretax Income
$ -48.26M$ -27.52M$ -19.03M$ -18.05M$ -14.79M
Net Income
$ -48.26M$ -27.52M$ -19.03M$ -18.05M$ -14.79M
Per Share Metrics
Basic EPS
$ -0.49$ -1.16$ -3.57$ -4.26$ -4.88
Diluted EPS
$ -0.49$ -1.16$ -3.57$ -4.26$ -4.88
Weighted Average Shares Outstanding
 98.31M 69.36M 5.33M 4.20M 3.03M
Weighted Average Shares Outstanding (Diluted)
 98.31M 69.36M 5.33M 4.20M 3.03M
Currency in USD

Inhibikase Therapeutics Earnings and Revenue History